Echo | Angio | ECG | X-Ray/MRI | Clinical Trials | Guidelines | Drug Info |  Journals  | Events | Interesting Cases

Welcome Oct 21, 2014
Search News by Date
  



New concept of stent, the Multilayer Flow Modulator has been developed to treat arterial aneurysms

Traditional treatment of arterial aneurysms has been surgical. However, interventional procedures even with a high technical success rate do not solve issues such as protection of aneurysm rupture, endoleaks, stent thrombosis, collateral branch thrombosis. Addressing this issue, Dr. Michel Henry and coworkers performed the present first in human study that developed a new concept of stent, the Multilayer Flow Modulator, a 3D braided tube made of several interconnected layers without any covering in the treatment of arterial aneurysms and attempted to avoid the few drawbacks encountered with endografts.

Moreover, researchers’ early results of in vitro (theorical simulation), computerized Fluid dynamics, Molecular Modelization and in vivo tests demonstrated Multilayer Flow Modulator to reduce the velocity in the aneurismal sac up to 90% by the modification of the hemodynamic conditions. Some other studies had also shown that a saccular aneurysm without collateral branch to thrombose quickly and also indicated that in the presence of a collateral branch, the flow is directed towards this branch leading to shrinkage of the aneurysm.  

Moreover, as demonstrated in animal and human studies, MFM preserved the collateral branches that allowed the possibility to cover any artery without a compromise in the flow (renal, digestive arteries, supra aortic vessels).

As a part of this study, a total of 39 peripheral Arterial aneurysms (iliac: 23, femoral:1, popliteal:5, renal:8, mesenteric:1, Subclavian: 1) were treated with the MFM* stents (males :30, mean age:  62±8 yrs, 51 stents with diameters 5 to 14 mm; length 40 to 120 mm) to treat these aneurysms, by femoral approach (38 cases), brachial approach (1 case),

All patients reported a technical success without complications. Additionally, all the arterial aneurysms thrombosed with a diameter reduction reported in some patients.

It was found that the time taken for thrombosis depended upon the importance of collateral branches and all the side branches remained patent.

In conclusion, this new concept of stent, the MFM* (without any covering) developed to treat arterial aneurysms with promising results opened a new approach in the treatment of peripheral Arterial aneurysms avoiding most of the complications encountered with current endovascular techniques. A larger study is still ongoing and 6 month to 36 month follow up data presented would discuss the time needed to achieve exclusion of the Arterial aneurysms.

 


Source:TCT 2012
Compiled and edited by the Editorial team and approved by Expert panel of CardioValens.com

 Other News
The Chocolate FIM Study: safety in use of the Chocolate Balloon catheter in the treatment of below the knee target lesions for reduced procedural complications and treatment success
High risks associated are payday loans websites and financial industry.

The Vancouver computed tomography sizing guidelines than the traditional TEE sizing recommendations are more standardized for the Transcatheter Replacement with Balloon Expandable Valves
1-Year Results of the DEFINITIVE LE Study supports the method of plaque excision for peripheral artery disease in critical limb ischemia patients
The Chocolate FIM Study: safety in use of the Chocolate Balloon catheter in the treatment of below the knee target lesions for reduced procedural complications and treatment success
ADAPT-DES IVUS sub-study results: frequency, timing, and correlates of an early and late DES thrombosis
Greater CD40L and TNF-B concentrations at the stenosis site in the superficial femoral artery are the markers for the disease progression of the newly diagnosed symptomatic patients, presently not employed on anti-platelets or a statin
Results from the INFUSE-AMI Trial: modest differences in infarct size between patients with and without CKD presenting with STEMI are unlikely to account for a significantly higher short-term cardiac risk in CKD
Similar safety with a polymer-free sirolimus, probucol-eluting stent vs. a new generation ZES at 2 years in the ISAR-TEST 5 trial
ISAR-LEFT MAIN 2: Similar 1 yr outcomes with Endeavor Resolute and Xience stents in high risk population
MASTER Trial: the MGuard Embolic Protection Stent, Inspire MD, a novel thin-strut metal stent designed with a PET micronet covering traps helps prevent an distal embolization

About Us | Disclaimer |  Privacy Statement | Advertising Info 
info@centrixhealthcare.com © Copyright 2000-2014 Centrix Healthcare Inc. - All Rights Reserved.